Syntara Reaches 50% Recruitment in Phase 2 Trial for Bone Marrow Cancer Treatment

Drug development company Syntara (ASX:SNT) reached 50% recruitment in its Phase 2 trial evaluating its lead candidate, SNT-5505, in combination with ruxolitinib, in the treatment of bone marrow cancer

MT NewswiresApr 9 22:09 ET

Syntara to Begin Phase Two Study for SNT-5505 Combination Therapy Later in 2024 After Government Grant

Drug development company Syntara (ASX:SNT) said Wednesday that a phase two study, examining the combined therapy of SNT-5505 with chemotherapy in individuals diagnosed with myelodysplastic syndrome (M

MT NewswiresFeb 13 23:14 ET

Syntara Opens Up to AU$2 Million Share Purchase Plan

Syntara (ASX:SNT) on Friday opened a share purchase plan priced at AU$0.022 per share to raise up to AU$2 million. The purchase plan will close Jan. 30, 2024, according to a Friday news release. Share

MT NewswiresDec 29, 2023 03:04 ET